Unearthing the latest in new drugsA look at novel agents in the late stages of development in Canada. Daxas: a new add-on therapy in severe COPDRoflumilast will be the first phosphodiesterase-4 (PDE4) inhibitor to be marketed in Canada. Levothyroxine: best taken at bedtime Llevothyroxine improves thyroid hormone levels more when taken at bedtime compared to morning on empty stomach. Bev Allen named 2010 Pillar of Pharmacy Award recipient Joins other distinguished award winners for his life-long commitment to the profession of pharmacy. New drugs get a rise out of HDL Phase II trials look promising, but larger outcome studies needed Opioid and diet pill bite the dust following safety concerns Best approach to oxycodone woes: Take it off the market Or, refuse to prescribe it to force drug-makers to end production Managing recurrent UTIs in women The Society of Obstetricians and Gynaecologists of Canada updates guidelines on treatment, prevention of recurrent urinary tract infections in women. Thelin (sitaxsentan): PAH drug withdrawn worldwide Pfizer Canada is voluntarily withdrawing Thelin from the market worldwide due to concerns about hepatotoxicity. Letter of concern to gov’t sparks quick ER responses In the wake of Dr. Paul Parks’ now famous e-mail outlining concern over ER overcrowding, the province has made some progress on the issue. First Previous 1090 1091 1092 1093 1094 Next Last
